S. Assadourian

发表

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Clinical Cancer Research.

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

J. Schellens, J. Beijnen, G. Sanderink, 2005, Cancer Chemotherapy and Pharmacology.

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

J. Schellens, J. Beijnen, J. Bonneterre, 2006, Clinical Cancer Research.

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies

J. Ajani, J. Soria, E. Deutsch, 2015, Oncology.

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours

P. Fumoleau, N. Isambert, V. Trillet-lenoir, 2012, British Journal of Cancer.

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

P. Fumoleau, N. Isambert, V. Trillet-lenoir, 2012, Clinical Cancer Research.

Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.

B. Geoerger, G. Vassal, B. Morland, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.

E. Van Cutsem, D. Khayat, C. Verslype, 2013, European journal of cancer.

Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.

E. Van Cutsem, D. Khayat, C. Verslype, 2013, European journal of cancer.

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer

Hyo Song Kim, Y. Bang, Jin-Hee Ahn, 2017, Oncotarget.

A phase I dose-ﬁnding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours

M. Piccart, A. Awada, R. Maes, 2006 .

Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)

R. Labianca, B. Nordlinger, G. Bodoky, 2005 .

A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs)

D. Khayat, C. Verslype, S. Tejpar, 2008 .

Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): Preliminary results

D. Khayat, C. Verslype, S. Tejpar, 2008 .

51A Docetaxel (D), cisplatin (C) 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325)

C. Boni, S. Tjulandin, E. Cutsem, 2003 .

Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.

J. Pierga, V. Girre, V. Diéras, 2013, European journal of cancer.

[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].

L. Mauriac, M. Tubiana-Hulin, A. Monnier, 2001, Bulletin du cancer.

A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).

B. Geoerger, G. Vassal, B. Morland, 2008, European journal of cancer.

A dose finding and pharmacokinetic study of docetaxel (TXT) and methotrexate (MTX) in patients with epithelial cancer

J. Droz, C. Ardiet, B. Tranchand, 1999 .

Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).

A. Tolcher, V. Boni, E. Calvo, 2013 .

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

J. Ajani, E. Van Cutsem, Y. Chao, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

F. de Marinis, V. Moreno, A. Hollebecque, 2017, European journal of cancer.

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

P. Philip, A. Santoro, P. Karásek, 2013, European journal of cancer.

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

M. Dimopoulos, P. Richardson, P. Moreau, 2020, Leukemia.

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.

M. Piccart, A. V. van Oosterom, A. Awada, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.

X. Pivot, J. Lotz, A. Chan, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter phase II study of XRP 6258 administered as a 1h i . v . infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

X. Pivot, J. Lotz, A. Chan, 2008 .

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

M. Namer, J. Bonneterre, A. Monnier, 2002, British Journal of Cancer.

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer

Y. Bang, Jin-Hee Ahn, T. Kudo, 2017, Oncotarget.

Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis

M. Dimopoulos, P. Richardson, P. Moreau, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

P. Fumoleau, N. Isambert, G. Freyer, 2012, Clinical Cancer Research.

Clinical results of docetaxel (D) and 5 fluorouracile (5FU) in metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN)

G. Calais, D. Cupissol, J. Dutin, 1999 .